Inhibition of MicroRNA-381 Promotes Tumor Cell Growth and Chemoresistance in Clear-Cell Renal Cell Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inhibition of MicroRNA-381 Promotes Tumor Cell Growth and Chemoresistance in Clear-Cell Renal Cell Carcinoma

Published:2019-07-12 Issue: Volume:25 Page:5181-5190
ISSN:1643-3750
Container-title:Medical Science Monitor
language:en
Short-container-title:Med Sci Monit

Author:

Chan Yunhui¹,Yu Yipeng²,Wang Gang²,Wang Changlin²,Zhang Daming³,Wang Xiaoxiong⁴,Wang Zichun²,Jian Wengang²,Zhang Cheng²

Affiliation:

1. Department of Urology, Third Ward, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland)

2. Department of Urology, Third Ward, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland)

3. Department of Pharmacology, Harbin Medical University, Harbin, Heilongjiang, China (mainland)

4. Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland)

Publisher

International Scientific Information, Inc.

Subject

General Medicine

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation;European Journal of Pharmacology;2023-09

2. Non-coding RNAs in renal cell carcinoma: Implications for drug resistance;Biomedicine & Pharmacotherapy;2023-08

3. Mining database and verification of PIK3CB as a marker predicting prognosis and immune infiltration in renal clear cell carcinoma;Medicine;2022-06-03

4. The Identification of Common Potential Biomarkersand Mechanism for Two Types of Renal Cancer;PROG BIOCHEM BIOPHYS;2022

5. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma;Cancer Cell International;2022-02-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3